MedPath

Levothyroxine

Generic Name
Levothyroxine
Brand Names
Eltroxin, Ermeza, Euthyrox, Levo-T, Levothroid, Levoxyl, Np Thyroid, Synthroid, Thyquidity, Tirosint, Unithroid
Drug Type
Small Molecule
Chemical Formula
C15H11I4NO4
CAS Number
51-48-9
Unique Ingredient Identifier
Q51BO43MG4
Background

Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quantities of the thyroid hormones T (tetraiodothyronine or thyroxine) and T (triiodothyronine or Liothyronine), resulting in diminished down-stream effects of these hormones. Without sufficient quantities of circulating thyroid hormones, symptoms of hypothyroidism begin to develop such as fatigue, increased heart rate, depression, dry skin and hair, muscle cramps, constipation, weight gain, memory impairment, and poor tolerance to cold temperatures.

In response to Thyroid Stimulating Hormone (TSH) release by the pituitary gland, a normally functioning thyroid gland will produce and secrete T, which is then converted through deiodination (by type I or type II 5′-deiodinases) into its active metabolite T. While T is the major product secreted by the thyroid gland, T exerts the majority of the physiological effects of the thyroid hormones; T and T have a relative potency of ~1:4 (T4:T3). T and T act on nearly every cell of the body, but have a particularly strong effect on the cardiac system. As a result, many cardiac functions including heart rate, cardiac output, and systemic vascular resistance are closely linked to thyroid status.

Prior to the development of levothyroxine, Thyroid, porcine or desiccated thyroid, used to be the mainstay of treatment for hypothyroidism. However, this is no longer recommended for the majority of patients due to several clinical concerns including limited controlled trials supporting its use. Desiccated thyroid products contain a ratio of T4 to T3 of 4.2:1, which is significantly lower than the 14:1 ratio of secretion by the human thyroid gland. This higher proportion of T3 in desiccated thyroid products can lead to supraphysiologic levels of T3 which may put patients at risk of thyrotoxicosis if thyroid extract therapy is not adjusted according to the serum TSH.

Indication

Levothyroxine is indicated as replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. It is also indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

Associated Conditions
Edematous Fibrosclerotic Panniculopathy (Cellulite), Hypothyroidism, Localized Adiposity, Myxedema coma, Euthyroid Goitre, Thyrotropin dependent Well-Differentiated Thyroid Cancer
Associated Therapies
-

Recovery Rate in Secondary Hypothyroidism

Recruiting
Conditions
Secondary Hypothyroidism
First Posted Date
2022-03-11
Last Posted Date
2024-08-21
Lead Sponsor
Nova Scotia Health Authority
Target Recruit Count
90
Registration Number
NCT05276856
Locations
🇨🇦

Nova Scotia Health, Halifax, Canada

Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused by Thyroidectomy in Thyroid Cancer Patients.

Phase 4
Conditions
Thyroid Cancer, Papillary
Hypothyroidism
Interventions
Drug: L-T4+T3 (thyroid tablet)
Drug: L-T4
First Posted Date
2022-02-18
Last Posted Date
2022-02-18
Lead Sponsor
Zhongshan Hospital Xiamen University
Target Recruit Count
50
Registration Number
NCT05247476
Locations
🇨🇳

Yan Ling, Xiamen, Fujian, China

Use of Tirosint®-SOL or Tablet Formulations of Levothyroxine in Pediatric Patients With Congenital Hypothyroidism (CH)

Phase 4
Active, not recruiting
Conditions
Congenital Hypothyroidism
Interventions
Drug: Tirosint®-SOL
Drug: Levothyroxine Sodium
First Posted Date
2022-02-08
Last Posted Date
2024-04-15
Lead Sponsor
IBSA Institut Biochimique SA
Target Recruit Count
126
Registration Number
NCT05228184
Locations
🇺🇸

CHOC Children's Hospital, Orange, California, United States

🇺🇸

Children's Hospital of Los Angeles, Los Angeles, California, United States

🇺🇸

Children's Hospital of Atlanta, Atlanta, Georgia, United States

and more 9 locations

The Effect of Thyroid Antibodies on Female Reproductive Function and Pregnancy Outcomes

Conditions
Thyroiditis, Autoimmune
Interventions
First Posted Date
2021-07-07
Last Posted Date
2021-07-07
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
4000
Registration Number
NCT04952012
Locations
🇨🇳

Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

The Prevalence and Risk Factors for Thyroid Dysfunction in Pregnant Women in Taiwan

Conditions
Thyroid Disease Pregnancy
Interventions
Drug: PTU 50 MG Oral Tablet
Drug: Levothyroxin
First Posted Date
2021-06-23
Last Posted Date
2021-08-16
Lead Sponsor
Chang Gung Memorial Hospital
Target Recruit Count
2000
Registration Number
NCT04936698
Locations
🇨🇳

Chang Gung Memorial hospital, Taipei City, Taiwan

Comparison of Levothyroxine Formulation in Hypothyroid Patients With Enteral Feeding

Phase 4
Terminated
Conditions
Hypothyroidism
Interventions
First Posted Date
2021-05-07
Last Posted Date
2023-04-10
Lead Sponsor
University of California, Los Angeles
Target Recruit Count
3
Registration Number
NCT04878614
Locations
🇺🇸

UCLA Center for Human Nutrition, Los Angeles, California, United States

Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid Cancer

Phase 1
Withdrawn
Conditions
Thyroid Cancer
Interventions
First Posted Date
2021-04-30
Last Posted Date
2023-02-21
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Registration Number
NCT04868045

Energy Metabolism in Thyroidectomized Patients

Phase 2
Completed
Conditions
Thyroid Goiter
Hypothyroidism
Thyroid Cancer
Interventions
First Posted Date
2021-03-04
Last Posted Date
2024-06-14
Lead Sponsor
Virginia Commonwealth University
Target Recruit Count
13
Registration Number
NCT04782856
Locations
🇺🇸

Virginia Commonwealth University, Richmond, Virginia, United States

Final Height in Patients With CH Diagnosed by the Screening

Conditions
Congenital Hypothyroidism
First Posted Date
2021-02-02
Last Posted Date
2021-10-05
Lead Sponsor
Ain Shams University
Target Recruit Count
60
Registration Number
NCT04734457
Locations
🇪🇬

Ain Shams University, Cairo, Abbasiya, Egypt

Thyroid and Adrenocortical Hormone Replacement in Organ Donors

Not Applicable
Completed
Conditions
Brain Death
Interventions
First Posted Date
2020-08-27
Last Posted Date
2020-08-27
Lead Sponsor
Medical University of South Carolina
Target Recruit Count
199
Registration Number
NCT04528797
© Copyright 2025. All Rights Reserved by MedPath